Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of daily rimegepant for prevention of chronic migraine
MOH_2026-06-21_016884Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rimegepant in chronic migraine (3 arms), sponsored by Pfizer. Started Jun 2026; status: recruiting.
02
Drugs
rimegepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on MOH_2026-06-21_016884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-21_016884.